JPRN-jRCT2080220307未知3 期
A study of R435(Bevacizmab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
适应症
试验速览
- 阶段
- 3 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •- >= 18 years of age, adult patients
- •- documented colon carcinoma
- •- not a candidate for (neo) adjuvant radiotherapy
- •- curative surgery not less than 4 and not more than 8 weeks prior to study randomization.
- •Exclusion criteria:
- •- evidence of metastatic disease
- •- previous anti-angiogenic treatment for any malignancy
- •-previous cytotoxic chemotherapy, radiotherapy, or immunotherapy for colon cancer
- •- pregnant or lactating women
- •- fertile men, or women of childbearing potential, not using adequate contraception
- •- major surgical procedures, open biopsy, or significant traumatic injury, within 28 days prior to study treatment start
- •- current or recent treatment (within 28 days prior to randomization) with another investigational drug, or participation in another investigational study
排除标准
- 未提供
研究者
相似试验
未知
3 期
A study of R435 (Bevacizumab) in Combination With R340 (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.Gastric CancerJPRN-jRCT2080220416Chugai Pharmaceutical Co., Ltd.
未知
3 期
Safety comformation study of R435 (Bevacizumab) in patients with metastatic colorectal cancerMetastatic colorectal cancerJPRN-jRCT2080220205Chugai Pharmaceutical Co., Ltd.
未知
3 期
A compassionate use study of R435(Bevacizumab) in chemotherapy naive and inoperable malignant pleural mesothelioma patientschemotherapy naive and inoperable malignant pleural mesotheliomaJPRN-jRCT2080223406CHUGAI PHARMACEUTICAL CO., LTD.12
未知
2 期
Phase II clinical study of R435 (bevacizumab) in combination with paclitaxel in patients with inoperable metastatic breast cancerInoperable metastatic breast cancerJPRN-jRCT2080220385Chugai Pharmaceutical Co., Ltd.
未知
1 期
Phase I/II study of R435 (Bevacizumab) in patients with metastatic colorectal cancerMetastatic colorectal cancerJPRN-jRCT2080220022Chugai Pharmaceutical Co., Ltd.